sellWeak cluster of 510b5-1 plan
Timothy Rolph sold $552k of AKRO
Chief Scientific Officer at Akero Therapeutics, Inc.. 12,500 shares at an average of $44.17, traded Sep 8, 2025, filed Sep 10, 2025.
Warning score
14Value
$552k
12,500 shares
Holdings after
167,124
-7% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +19Trade size$552k at market
- 0Share of holdings soldSold 7.0% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001779479-25-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 8, 2025 | MOption exercise Common Stock10b5-1 | +7,044 | $21.09 | $149k | 174,168 | Sep 10, 2025 |
| Sep 8, 2025 | MOption exercise Common Stock10b5-1 | +5,161 | $6.36 | $33k | 179,329 | Sep 10, 2025 |
| Sep 8, 2025 | MOption exercise Common Stock10b5-1 | +295 | $28.35 | $8,363 | 179,624 | Sep 10, 2025 |
| Sep 8, 2025 | SOpen-market sale Common Stock10b5-1 | -12,466 | $44.17 | $551k | 167,158 | Sep 10, 2025 |
| Sep 8, 2025 | SOpen-market sale Common Stock10b5-1 | -34 | $44.88 | $1,526 | 167,124 | Sep 10, 2025 |
| Sep 8, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -7,044 | $0.00 | $0 | 389 | Sep 10, 2025 |
| Sep 8, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -295 | $0.00 | $0 | 62,445 | Sep 10, 2025 |
| Sep 8, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,161 | $0.00 | $0 | 0 | Sep 10, 2025 |
Related signals
Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $1.4M 31,796 shares | -6% | |
| 30Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $24k 553 shares | -0% | |
| 42Moderate | Akero Therapeutics, Inc. | William Richard White Chief Financial Officer | $28k 659 shares | -1% | |
| 35Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $28k 659 shares | -1% | |
| 40Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $25k 586 shares | -0% | |
| 19Weak | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $576k 12,500 shares | -6% | |
| 45Moderate | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $1.5M 30,000 shares | -6% | |
| 19Weak | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $597k 12,500 shares | -6% | |
| 31Weak | Akero Therapeutics, Inc. | Jane Henderson director | $142k 3,000 shares | -24% | |
| 15Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $616k 12,500 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.